Antares Pharma, Inc. (AIS) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-19.84M
Depreciation and amortization	1.37M
Gain on sale of equipment, molds, furniture and fixtures	17.79K
Stock-based compensation expense	1.89M
Accounts receivable	-624.23K
Inventories	-999.16K
Prepaid expenses and other current assets	2.92M
Deferred costs	-762.41K
Accounts payable	3.31M
Accrued expenses and other current liabilities
Deferred revenue	1.16M
Net cash used in operating activities
Purchases of equipment, molds, furniture and fixtures	-4.28M
Additions to patent rights	-103.79K
Proceeds from sales of equipment, molds, furniture and fixtures
Net cash used in investing activities
Proceeds from exercise of stock options and warrants
Proceeds from sale of common stock	0
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Beginning of period
End of period

Entities mentioned with AIS

View All Entities